Global Opioids
Market Report
2025

Opioids Market Report 2025 (Global Edition)

Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.

Author Name: Manjiri Kanhere | Report ID: CMR499572 |

The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.

Data Updated: November 2024 | Report Pages: 250+ | Edition: 8th |

PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.

Format:

Rating: 4.8 | Review: 23

| Last Updated: 2024-07-30T14:19:53-06:00

Share your contact details to receive free updated sample copy/pages of the recently published edition of Opioids Market Report 2024.

Global Opioids Market Report 2024 Market Size Split by Product (Codeine, Methadone, Morphine, Oxycodone, Fentanyl, Hydrocodone, Others), by Application (Pain Management, Diarrhea Treatment, Cough Trea...

According to Cognitive Market Research, the Global Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
The hospital pharmacies had a market share of about XX% in 2023.
The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Preview of Global Opioids Market Revenue

Opioids Market Size, CAGR and Industry Statistics

Base Year	2023
Historical Data Time Period	2019-2023
Forecast Period	2024-2031
Global Opioids Market Sales Revenue 2020	$ 4.37 Billion
Global Opioids Market Sales Revenue 2030	$ 5.85 Billion
Global Opioids Market Compound Annual Growth Rate (CAGR) for 2024 to 2031	3.28%
Market Drivers: Rising prevalence of chronic pain conditions globally
Market Restrains: Opioid addiction and its side effects pose significant challenges to the market
Market Trends: The rapid increase in the demand for retail pharmacies can be an opportunity for the market

Industry segmentation can be altred as per your needs. For example, we can proivde cross slipt between Codeine with Application, Route of Administration, additional country analysis, volume/consumption data, etc.

Opioids Market Report Scope

Market Split by Product	Codeine Methadone Morphine Oxycodone Fentanyl Hydrocodone Others
Market Split by Application	Pain Management Diarrhea Treatment Cough Treatment Deaddiction Anesthesia
Market Split by Route of Administration	Oral Injectable Transdermal Patch Others
Market Split by Drug Class	Immediate-Release/Short-Acting Opioids Extended-Release /Long-Acting Opioids
Market Split by End User	Hospitals Homecare Speciality Centre Others
Market Split by Distribution Channel	Hospital Pharmacy Retail Pharmacy Online Pharmacy Others
Market Split by Conclusion
List of Competitors	Purdue Pharma L.P Sanofi Johnson & Johnson Services Inc AbbVie Inc. Sun Pharmaceutical Industries Ltd Pfizer Inc. Bayer AG Mallinckrodt Pharmaceuticals GlaxoSmithKline plc Aurobindo Pharma Fresenius Kabi Amneal Pharmaceuticals Endo International plc. Trevena Inc. Hikma Pharmaceuticals Rusan Pharma Ltd Lupin Limited Abbott Laboratories Novartis AG Assertio Therapeutics Inc.+ Confidential Data Access The Paid Version Data Hidden
Regional Analysis	North America Europe Asia-Pacific South America Middle East and Africa
Country Analysis	North America (United States, Canada, Mexico) Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium, Rest of Europe) Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC) South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America) Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

Report scope is customizable as we have a huge database of Opioids industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

Opioids Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!

Opioids Market Report Description

Introduction of Opioids Market

Opioids are medicines that are used for the treatment of persistent and severe pain, such as chronic backaches and headaches as well as for managing pain after surgery. It is a class of drugs that act on the nervous system to relieve pain. They are derived from opium or synthetic versions that mimic the effects of natural opium compounds. Many patients rely on prescribed opioids to help them manage their ailments while under the care of a doctor. When it comes to reducing moderate to severe pain, opioids are very effective. They reduce the experience of pain by attaching to opioid receptors in the brain, spinal cord, and other areas of the body. When someone is in excruciating pain following surgery, an injury, or a medical condition like cancer, opioids can be a lifesaver. They can also be applied in palliative care to lessen suffering towards the end of life. The opioid market is witnessing growth owing to the increasing prevalence of orthopedic diseases and chronic pain, rising focus on the abuse-deterrent formulation (ADF), rising palliative care facilities, and inclination towards extended-release formulations from the immediate release of opioids. The increase in ailments including cancer, lung infections, HIV, and an expansion in surgical procedures has fueled the growth of the opioid industry. The increasing approval and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth. For instance, in August 2020, the Food and Drug Administration in the U.S. approved Olinvyk (oliceridine), an injection developed by Trevena, Inc., for treating adults with acute pain. Olinvyk is an opioid agonist administrated intravenously to patients and costs around USD 194 for a supply of 10 mL.
(Source-https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings)

Opioids Market Size

Market Dynamics of the Opioids

Rising prevalence of chronic pain conditions globally

The increased prescription of painkillers during post-operative procedures and an increase in patients with terminally chronic pain or diseases including HIV, and severe cough brought on by lung infections are two causes that are anticipated to increase opioid use as a pain reliever. Chronic pain affects an estimated 20% of the global population, with conditions such as arthritis, cancer, and lower back pain contributing to the growing demand for effective pain management solutions. In the past, it resulted in a demand surge for opioids and boosted growth. Another factor for the growth of the opioid drug market is the spike in the number of surgeries. According to the National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention (CDC) in 2019, the prevalence of high-impact chronic pain in the United States was 7.4 percent.

(Source-https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf)

The aging population’s vulnerability is at high risk of chronic diseases such as cardiovascular diseases, arthritis, and cancer due to the high comorbid conditions. Declining fertility and mortality rates are some factors contributing to the geriatric population's rise. The impact of chronic pain increases with age and is highest among adults aged 65 years and above. Therefore, the rising geriatric population is anticipated to increase the demand for opioid drugs to manage chronic pain. According to the World Health Organization (WHO), the geriatric population increased from 1.0 million in 2020 to 1.4 million in 2021.

(Source-https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Opioid addiction and its side effects pose significant challenges to the market

One of the major challenges for this market is the high potential for abuse and addiction, physicians have scaled back their pain management prescriptions, decreasing global scales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers. The patient may become tolerant and need more and more drugs to achieve the effect of smoothing the pain. Moreover, using opioids for an extended period can develop a dependency, and after leaving the drug, the patient may suffer from withdrawal symptoms such as anxiety, irritability, drug cravings, tremors (shaking), and others. The heightened regulatory scrutiny has resulted in stricter guidelines for prescribing opioids, impacting accessibility for patients in genuine need of pain relief. Regulatory changes often aim to strike a balance between ensuring access for patients and preventing misuse. The forecasted period illustrates a decrease in the opioid market growth due to the adversities and the negative effects of opioids. Researchers and experts have considered this and are making constant efforts to reduce and minimize the negative side effects of opioids. As per the record, drug overdose in the year 2018, had 657 deaths.

(Source-https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-august-2018/download)

Furthermore, the Millennium Health's Signals report (2020) revealed that there was a rise in non-prescribed fentanyl by 31.96%, methamphetamine by 19.96%, Cocaine by 10.06% and heroin by 12.53% from March to May 2020. Thus, the implementation of strict regulation on the use of opioids is expected to restrain the market growth during the forecast period.
(Source-https://www.millenniumhealth.com/news/signalsreportcovid/)

The rapid increase in the demand for retail pharmacies can be an opportunity for the market

There are ample opportunities for market expansion owing to the rise in open-angle glaucoma treatments delivered through retail pharmacies and the rise in retail pharmacies in highly developed nations. Patients also prefer to buy medications from retail pharmacies since they are convenient and easily available. Pharmaceutical companies are investing in research and development to create opioids that offer effective pain relief with a reduced risk of abuse and side effects. Furthermore, the increasing adoption of personalized medicine approaches allows for more tailored opioid therapies, optimizing efficacy and minimizing risks. The rapid increase in approval rates and the introduction of new opioid medications for treating patients with chronic pain are expected to provide growth opportunities for the market over the forecast period. The key market players are focused on inorganic growth strategies such as acquisition to enter into the opioid drugs market to address the ongoing challenges and meet the unmet needs in pain management, driving future growth in the opioids market.

How did COVID-19 Impact the Opioids?

The Opioids Market has experienced significant impacts as a result of the COVID-19 pandemic. The pandemic led to a lot of disruptions and commotions in the supply chains leading to postponements and delays in the manufacturing and distribution of the medicines Different disturbances like worldwide lockdowns, closing down factories, and restrictions on transportation impacted the availability of raw materials and types of equipment. During the initial phase of COVID-19, the market for opioids was negatively impacted due to the low hospitalization rate, COVID-19-mandated changes in policy, and a decline in surgeries and dental procedures led to a reduction in opioid prescriptions. During the COVID-19 pandemic, a further substantial increase in drug overdose deaths was reported in the USA, primarily driven by rapid increases in overdose deaths involving synthetic opioids.

(Source-https://www.who.int/news-room/fact-sheets/detail/opioid-overdose)

The COVID-19 pandemic in the United States forced healthcare systems to shift resources toward COVID-19-designated sites and intensive care units. To reduce the risk of the virus spreading, non-urgent and emergency outpatient chronic pain services were cut or discontinued during the COVID-19 Pandemic 2020. People with chronic pain tend to be isolated, which has negative psychological and social effects. During the COVID-19 epidemic, the US government's lockdown had an impact on chronic pain management. In 2022, 7.9 million Canadians, or one in five, will experience chronic pain, according to the government. The emotional, bodily, and familial health as well as the economy of Canada were all severely impacted by chronic pain. During the projected period, these factors will lead to a notable increase in the market. It also has some positive effects on the market as it acts as a pain-reducing agent. Also, a large number of the population started to accumulate and save opioid medicine due to government restrictions. During the pandemic, the market grew because of increased health concerns, rising chronic diseases, and growing demand for opioids. The opioid market is estimated to grow significantly and have a huge effect during the COVID-19 era.

Recent Developments

In April 2024, Hikma Pharmaceuticals PLC acquired a portfolio of opioid analgesics from Xellia. This acquisition is expected to strengthen Hikma’s market position and expand its offerings in pain management solutions.

(Source-https://www.hikma.com/news/hikma-acquires-xellia-s-differentiated-portfolio-and-enhances-injectables-pipeline-manufacturing-capabilities-and-rd/)

In January 2023, Major pharmaceutical company Lupin Limited (Lupin) stated that their New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide (DETAF) Tablets had gained provisional approval from the U.S. Food and Drug Administration (FDA) under PEPFAR. This product would be produced in the Lupin factory in Nagpur, India.

(Source-https://www.lupin.com/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-detaf-tablets/)

In December 2022, According to a recent announcement from Endo International plc (OTC: ENDPQ), the company will no longer manufacture or market Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) due to market concerns regarding the degree and variability of bruising after initial treatment as well as the possibility of long-term skin discoloration.

(Source-https://www.endoaesthetics.com/qwo/)

In August 2020, the FDA approved Olinvyk injection which was developed by Trevena, Inc., for treating adults with severe acute pain. Olinvyk is an opioid agonist administrated intravenously to patients that costs about USD 194 for a supply of 10 mL vial.

(Source-https://www.trevena.com/investors/press-releases/detail/335/trevena-awarded-olinvyk-agreement-with-premier-inc)

In June 2021, the U.S. FDA accepted and granted priority review designation to new drug application (NDA) submitted by Purdue Pharma L.P. for nalmefene hydrochloride injection. Nalmefene injectable is an opioid antagonist designed to reverse opioid overdose

(Source-https://www.fda.gov/news-events/press-announcements/fda-approves-prescription-nasal-spray-reverse-opioid-overdose)

In February 2024, Johnson & Johnson Services, Inc. introduced a novel opioid analgesic patch designed for chronic pain management. The new patch offers sustained pain relief over 72 hours, aiming to improve patient compliance and comfort.

(Source-https://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf)

We have various report editions of Opioids Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape: Opioids Market

To meet the increasing demands of consumers the industry players are now investing and giving more attention to their research and development of Opioids so that they sustain and survive in the competition. ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Top Companies Market Share in Opioids Industry: (In no particular order of Rank)

Purdue Pharma L.P
Sanofi
Johnson & Johnson Services Inc
AbbVie Inc.
Sun Pharmaceutical Industries Ltd
Pfizer Inc.
Bayer AG
Mallinckrodt Pharmaceuticals
GlaxoSmithKline plc
Aurobindo Pharma
Fresenius Kabi
Amneal Pharmaceuticals
Endo International plc.
Trevena Inc.
Hikma Pharmaceuticals
Rusan Pharma Ltd
Lupin Limited
Abbott Laboratories
Novartis AG
Assertio Therapeutics Inc.+
Confidential Data
Access The Paid Version
Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Opioids Market in 2024?

According to Cognitive Research, the North American region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future. This growth is supported by increasing approval of opioid-based medicines to meet rising unmet medical needs in the region. Moreover, improved healthcare infrastructure and increased awareness of pain management options have led to higher opioid prescription rates, positively impacting the opioid market demand. The growth of the opioid market in the region is driven by increased demand in key countries United States and Canada. For Instance, Hikma Pharmaceuticals introduced a generic version of Buprenex, an injection of buprenorphine hydrochloride, in May 2020. Buprenex is a prescription opioid used to treat patients with moderate to severe pain in the United States. This injection aids in the treatment of extreme pain. The cost of an intravenous 5 mL injection solution is around USD 89.
(Source-https://www.hikma.com/media/szfbtmz3/ww20401-buprenorphine-inj-pr-final.pdf)

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is projected to grow at a CAGR of XX% over the period. It is due to the figure of elderly people, growth in the awareness about accessibility of healthcare facilities, and escalation in the number of chronic disorders. The region’s growth owing to the initiatives undertaken by the government to control opioid misuse in the region. For Instance, the New Zealand Medicines and Medical Devices Safety Authority (Med Safe) intended to implement warning labels on the possibility of opioid overdose on opioid medications in February 2022. This policy may lead to a higher prescription rate for premium opioids used for pain relief, which would fuel the opioid market's expansion.
(Source-https://www.raps.org/news-and-articles/news-articles/2022/2/asia-pacific-roundup-new-zealand-seeks-feedback-on)

The current report Scope analyzes Opioids Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

North America (United States, Canada, Mexico)
Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

Opioids Market Share (%) by Region (2019-2031)

The above graph is for illustrative purposes only.

To learn more about geographical trends request the free sample pages.

Get Free Sample

North America Opioids Market

According to Cognitive Market Research, the North America Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Europe Opioids Market

According to Cognitive Market Research, the Europe Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Asia-Pacific Opioids Market

According to Cognitive Market Research, the Asia-Pacific Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

South America Opioids Market

According to Cognitive Market Research, the South America Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Middle East and Africa Opioids Market

According to Cognitive Market Research, the Middle East and Africa Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Opioids Market Analysis

Global Opioids Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Opioids Industry growth. Opioids market has been segmented with the help of its Product, Application Route of Administration, and others. Opioids market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Product Segment Analysis of Opioids Market

Based on present and future trends, the market size is estimated from 2019 to 2031. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Opioids market.

Product of Opioids analyzed in this report are as follows:

Codeine
Methadone
Morphine
Oxycodone
Fentanyl
Hydrocodone
Others

Opioids Market Share (%) by Product in 2019-2031

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Opioids Industry. Request a Free Sample PDF!

The Pain Relief segment accounts for the largest market share and is expected to rise over the period it is because of the extensive requirement for efficient pain mitigation strategies. Opioids stand out as potent analgesics, delivering swift and substantial pain alleviation, and are indispensable for individuals grappling with severe or persistent pain issues. For Instance, The National Library of Medicine (2020) estimates that around 310.0 million operations are carried out annually worldwide, with 20.0 million and 40.0 to 50.0 million of those procedures occurring in Europe and the United States, respectively. Consequently, a rise in surgical procedures raises the need for medications to control pain following surgery.
(Source-https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388795/)
The Anesthesia is anticipated to grow at the fastest CAGR during the forecast period. Opioids are commonly used by anesthesiologists to induce and maintain Anesthesia, manage intraoperative pain, and provide post-operative pain relief. Intravenous opioids are commonly used to provide analgesia and supplement sedation during general Anesthesia. Additionally, the precision and efficacy of opioids in controlling pain during Anesthesia make them a preferred choice, reinforcing their substantial presence in the Anesthesia sector of the opioids market.

Opioids Market Share (%) by Application in 2019-2031

2019

2023

2031

The above Graph is for representation purposes only. This chart does not depict actual Market share.

To learn more about market share request the free sample pages.

Get Free Sample

Opioids Route of Administration Segment Analysis

Oral
Injectable
Transdermal Patch
Others

Opioids Drug Class Segment Analysis

Immediate-Release/Short-Acting Opioids
Extended-Release /Long-Acting Opioids

Opioids End User Segment Analysis

Hospitals
Homecare
Speciality Centre
Others

Opioids Distribution Channel Segment Analysis

The hospital pharmacies segment accounts for the largest market share and is expected to rise over the period as these settings are the first encounters with opioid prescriptions for patients, especially after surgeries or for acute pain management. The competitive environment is projected to get more intense as more significant pharmaceutical companies enter the oncology market, which is one of the most lucrative areas of the sales segment in hospital pharmacies. The retail pharmacies segment is anticipated to grow at the fastest CAGR during the forecast period due to its accessibility and widespread distribution network. It serves as the most accessible point for patients to fill opioid prescriptions for chronic pain management. Patients receive prescriptions from healthcare providers and fill them conveniently at these pharmacies. It offers widespread availability, convenience, and, in some regions, counseling services to ensure safe use, boosting the opioid market revenue.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Bio :

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.

In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.

Author's Conclusion

With the help of the above study about the Opioids market, it can be concluded that the market for Opioids worldwide is expected to develop significantly in the near future. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Frequently Asked Questions (FAQs)

What is the growth rate for the Opioids Market?

Opioids Market size will grow at approximately a CAGR of XX% during the forecast period.

Who are the prominent players in the Opioids Market?

Some of the top industry players in the Opioids Market are, Purdue Pharma L.P, Sanofi, Johnson & Johnson Services, Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd, Pfizer Inc., Bayer AG, Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc, Aurobindo Pharma, Fresenius Kabi, Amneal Pharmaceuticals & Endo International plc.

Which is the region that holds the majority share of the Opioids Market?

In the Opioids Market, North–America has established itself as the market leader with a significant market share.

Which region shows the most rapid expansion in the Opioids Market?

The Opioids Market has seen the most substantial growth rate in Asia-Pacific.

Which are the various segments that the global Opioids Market report covers?

The Global Opioids Market report is segmented as follows: By Product Type, By Drug Class, By Route of Administration By Application, By User, By distribution channel & By Region.

Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.

Latest News about Opioids Market

https://www.hikma.com/news/hikma-acquires-xellia-s-differentiated-portfolio-and-enhances-injectables-pipeline-manufacturing-capabilities-and-rd/

https://www.lupin.com/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-detaf-tablets/

https://www.trevena.com/investors/press-releases/detail/335/trevena-awarded-olinvyk-agreement-with-premier-inc

Sources from Pharma & Healthcare Industry

Opioids Market Report Table of Content

Disclaimer:

This is just a redacted sample pages of the actual deliverable report and only for representative purposes
Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
If applicable; On Request Volume Data will also be provided (at an Additional Cost).

Report Scope

Product	Codeine, Methadone, Morphine, Oxycodone, Fentanyl, Hydrocodone, Others
Application	Pain Management, Diarrhea Treatment, Cough Treatment, Deaddiction, Anesthesia
Route of Administration	Oral, Injectable, Transdermal Patch, Others
Drug Class	Immediate-Release/Short-Acting Opioids, Extended-Release /Long-Acting Opioids
End User	Hospitals, Homecare, Speciality Centre, Others
Distribution Channel	Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
Conclusion
List of Competitors	Purdue Pharma L.P, Sanofi, Johnson & Johnson Services Inc, AbbVie Inc., Sun Pharmaceutical Industries Ltd, Pfizer Inc., Bayer AG, Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc, Aurobindo Pharma, Fresenius Kabi, Amneal Pharmaceuticals, Endo International plc., Trevena Inc., Hikma Pharmaceuticals, Rusan Pharma Ltd, Lupin Limited, Abbott Laboratories, Novartis AG, Assertio Therapeutics Inc.+

Expand All

This chapter will help you gain GLOBAL Market Analysis of Opioids. Further deep in this chapter, you will be able to review Global Opioids Market Split by various segments and Geographical Split.

Chapter 1 Global Market Analysis

1.1 Global Opioids Revenue Market Size, Trend Analysis 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

1.2 Global Opioids Market Size By Regions 2019 - 2031
- 1.2.1 Global Opioids Revenue Market Size By Region
1.3 Global Opioids Market Size By Product 2019 -2031
- 1.3.1 Codeine Market Size
- 1.3.2 Methadone Market Size
- 1.3.3 Morphine Market Size
- 1.3.4 Oxycodone Market Size
- 1.3.5 Fentanyl Market Size
- 1.3.6 Hydrocodone Market Size
- 1.3.7 Others Market Size
1.4 Global Opioids Market Size By Application 2019 -2031
- 1.4.1 Pain Management Market Size
- 1.4.2 Diarrhea Treatment Market Size
- 1.4.3 Cough Treatment Market Size
- 1.4.4 Deaddiction Market Size
- 1.4.5 Anesthesia Market Size
1.5 Global Opioids Market Size By Route of Administration 2019 -2031
- 1.5.1 Oral Market Size
- 1.5.2 Injectable Market Size
- 1.5.3 Transdermal Patch Market Size
- 1.5.4 Others Market Size
1.6 Global Opioids Market Size By Drug Class for 2019 -2031
- 1.6.1 Immediate-Release/Short-Acting Opioids Market Size
- 1.6.2 Extended-Release /Long-Acting Opioids Market Size
1.7 Global Opioids Market Size By End User for 2019 -2031
- 1.7.1 Hospitals Market Size
- 1.7.2 Homecare Market Size
- 1.7.3 Speciality Centre Market Size
- 1.7.4 Others Market Size
1.8 Global Opioids Market Size By Distribution Channel for 2019 -2031
- 1.8.1 Hospital Pharmacy Market Size
- 1.8.2 Retail Pharmacy Market Size
- 1.8.3 Online Pharmacy Market Size
- 1.8.4 Others Market Size
- 1.8.1 Hospital Pharmacy Market Size
- 1.8.2 Retail Pharmacy Market Size
- 1.8.3 Online Pharmacy Market Size
- 1.8.4 Others Market Size
1.9 Global Opioids Market Size By Conclusion for 2019 -2031
1.10 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)

1.11 Executive Summary Global Market (2019 vs 2024 vs 2031)
- 1.11.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
- 1.11.2 Global Market Revenue Split By Product
- 1.11.3 Global Market Revenue Split By Application
- 1.11.4 Global Market Revenue Split By Route of Administration
- 1.11.5 Global Market Revenue Split By Drug Class
- 1.11.6 Global Market Revenue Split By End User
- 1.11.7 Global Market Revenue Split By Conclusion
- Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
  
  1.11.8 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities

This chapter will help you gain North America Market Analysis of Opioids. Further deep in this chapter, you will be able to review North America Opioids Market Split by various segments and Country Split.

Chapter 2 North America Market Analysis

2.1 North America Opioids Market Size 2019 - 2031
- 2.1.1 North America Opioids Market Size By Country 2019 - 2031
- 2.1.2 North America Opioids Market Size by Product 2019 -2031
  - 2.1.2.1 North America Codeine Market Size
  - 2.1.2.2 North America Methadone Market Size
  - 2.1.2.3 North America Morphine Market Size
  - 2.1.2.4 North America Oxycodone Market Size
  - 2.1.2.5 North America Fentanyl Market Size
  - 2.1.2.6 North America Hydrocodone Market Size
  - 2.1.2.7 North America Others Market Size
- 2.1.3 North America Opioids Market Size by Application 2019 -2031
  - 2.1.3.1 North America Pain Management Market Size
  - 2.1.3.2 North America Diarrhea Treatment Market Size
  - 2.1.3.3 North America Cough Treatment Market Size
  - 2.1.3.4 North America Deaddiction Market Size
  - 2.1.3.5 North America Anesthesia Market Size
- 2.1.4 North America Opioids Market Size by Route of Administration 2019 -2031
  - 2.1.4.1 North America Oral Market Size
  - 2.1.4.2 North America Injectable Market Size
  - 2.1.4.3 North America Transdermal Patch Market Size
  - 2.1.4.4 North America Others Market Size
- 2.1.5 North America Opioids Market Size by Drug Class 2019 -2031
  - 2.1.5.1 North America Immediate-Release/Short-Acting Opioids Market Size
  - 2.1.5.2 North America Extended-Release /Long-Acting Opioids Market Size
- 2.1.6 North America Opioids Market Size by End User 2019 -2031
  - 2.1.6.1 North America Hospitals Market Size
  - 2.1.6.2 North America Homecare Market Size
  - 2.1.6.3 North America Speciality Centre Market Size
  - 2.1.6.4 North America Others Market Size
- 2.1.7 North America Opioids Market Size by Distribution Channel 2019 -2031
  - 2.1.7.1 North America Hospital Pharmacy Market Size
  - 2.1.7.2 North America Retail Pharmacy Market Size
  - 2.1.7.3 North America Online Pharmacy Market Size
  - 2.1.7.4 North America Others Market Size
- 2.1.8 North America Opioids Market Size by Conclusion 2019 -2031

This chapter will help you gain Europe Market Analysis of Opioids. Further deep in this chapter, you will be able to review Europe Opioids Market Split by various segments and Country Split.

Chapter 3 Europe Market Analysis

3.1 Europe Opioids Market Size 2019 - 2031
- 3.1.1 Europe Opioids Market Size By Country 2019 - 2031
- 3.1.2 Europe Opioids Market Size by Product 2019 -2031
  - 3.1.2.1 Europe Codeine Market Size
  - 3.1.2.2 Europe Methadone Market Size
  - 3.1.2.3 Europe Morphine Market Size
  - 3.1.2.4 Europe Oxycodone Market Size
  - 3.1.2.5 Europe Fentanyl Market Size
  - 3.1.2.6 Europe Hydrocodone Market Size
  - 3.1.2.7 Europe Others Market Size
- 3.1.3 Europe Opioids Market Size by Application 2019 -2031
  - 3.1.3.1 Europe Pain Management Market Size
  - 3.1.3.2 Europe Diarrhea Treatment Market Size
  - 3.1.3.3 Europe Cough Treatment Market Size
  - 3.1.3.4 Europe Deaddiction Market Size
  - 3.1.3.5 Europe Anesthesia Market Size
- 3.1.4 Europe Opioids Market Size by Route of Administration 2019 -2031
  - 3.1.4.1 Europe Oral Market Size
  - 3.1.4.2 Europe Injectable Market Size
  - 3.1.4.3 Europe Transdermal Patch Market Size
  - 3.1.4.4 Europe Others Market Size
- 3.1.5 Europe Opioids Market Size by Drug Class 2019 -2031
  - 3.1.5.1 Europe Immediate-Release/Short-Acting Opioids Market Size
  - 3.1.5.2 Europe Extended-Release /Long-Acting Opioids Market Size
- 3.1.6 Europe Opioids Market Size by End User 2019 -2031
  - 3.1.6.1 Europe Hospitals Market Size
  - 3.1.6.2 Europe Homecare Market Size
  - 3.1.6.3 Europe Speciality Centre Market Size
  - 3.1.6.4 Europe Others Market Size
- 3.1.7 Europe Opioids Market Size by Distribution Channel 2019 -2031
  - 3.1.7.1 Europe Hospital Pharmacy Market Size
  - 3.1.7.2 Europe Retail Pharmacy Market Size
  - 3.1.7.3 Europe Online Pharmacy Market Size
  - 3.1.7.4 Europe Others Market Size
- 3.1.8 Europe Opioids Market Size by Conclusion 2019 -2031

This chapter will help you gain Asia Pacific Market Analysis of Opioids. Further deep in this chapter, you will be able to review Asia Pacific Opioids Market Split by various segments and Country Split.

Chapter 4 Asia Pacific Market Analysis

4.1 Asia Pacific Opioids Market Size 2019 - 2031
- 4.1.1 Asia Pacific Opioids Market Size By Country 2019 - 2031
- 4.1.2 Asia Pacific Opioids Market Size by Product 2019 -2031
  - 4.1.2.1 Asia Pacific Codeine Market Size
  - 4.1.2.2 Asia Pacific Methadone Market Size
  - 4.1.2.3 Asia Pacific Morphine Market Size
  - 4.1.2.4 Asia Pacific Oxycodone Market Size
  - 4.1.2.5 Asia Pacific Fentanyl Market Size
  - 4.1.2.6 Asia Pacific Hydrocodone Market Size
  - 4.1.2.7 Asia Pacific Others Market Size
- 4.1.3 Asia Pacific Opioids Market Size by Application 2019 -2031
  - 4.1.3.1 Asia Pacific Pain Management Market Size
  - 4.1.3.2 Asia Pacific Diarrhea Treatment Market Size
  - 4.1.3.3 Asia Pacific Cough Treatment Market Size
  - 4.1.3.4 Asia Pacific Deaddiction Market Size
  - 4.1.3.5 Asia Pacific Anesthesia Market Size
- 4.1.4 Asia Pacific Opioids Market Size by Route of Administration 2019 -2031
  - 4.1.4.1 Asia Pacific Oral Market Size
  - 4.1.4.2 Asia Pacific Injectable Market Size
  - 4.1.4.3 Asia Pacific Transdermal Patch Market Size
  - 4.1.4.4 Asia Pacific Others Market Size
- 4.1.5 Asia Pacific Opioids Market Size by Drug Class 2019 -2031
  - 4.1.5.1 Asia Pacific Immediate-Release/Short-Acting Opioids Market Size
  - 4.1.5.2 Asia Pacific Extended-Release /Long-Acting Opioids Market Size
- 4.1.6 Asia Pacific Opioids Market Size by End User 2019 -2031
  - 4.1.6.1 Asia Pacific Hospitals Market Size
  - 4.1.6.2 Asia Pacific Homecare Market Size
  - 4.1.6.3 Asia Pacific Speciality Centre Market Size
  - 4.1.6.4 Asia Pacific Others Market Size
- 4.1.7 Asia Pacific Opioids Market Size by Distribution Channel 2019 -2031
  - 4.1.7.1 Asia Pacific Hospital Pharmacy Market Size
  - 4.1.7.2 Asia Pacific Retail Pharmacy Market Size
  - 4.1.7.3 Asia Pacific Online Pharmacy Market Size
  - 4.1.7.4 Asia Pacific Others Market Size
- 4.1.8 Asia Pacific Opioids Market Size by Conclusion 2019 -2031

This chapter will help you gain South America Market Analysis of Opioids. Further deep in this chapter, you will be able to review South America Opioids Market Split by various segments and Country Split.

Chapter 5 South America Market Analysis

5.1 South America Opioids Market Size 2019 - 2031
- 5.1.1 South America Opioids Market Size By Country 2019 - 2031
- 5.1.2 South America Opioids Market Size by Product 2019 -2031
  - 5.1.2.1 South America Codeine Market Size
  - 5.1.2.2 South America Methadone Market Size
  - 5.1.2.3 South America Morphine Market Size
  - 5.1.2.4 South America Oxycodone Market Size
  - 5.1.2.5 South America Fentanyl Market Size
  - 5.1.2.6 South America Hydrocodone Market Size
  - 5.1.2.7 South America Others Market Size
- 5.1.3 South America Opioids Market Size by Application 2019 -2031
  - 5.1.3.1 South America Pain Management Market Size
  - 5.1.3.2 South America Diarrhea Treatment Market Size
  - 5.1.3.3 South America Cough Treatment Market Size
  - 5.1.3.4 South America Deaddiction Market Size
  - 5.1.3.5 South America Anesthesia Market Size
- 5.1.4 South America Opioids Market Size by Route of Administration 2019 -2031
  - 5.1.4.1 South America Oral Market Size
  - 5.1.4.2 South America Injectable Market Size
  - 5.1.4.3 South America Transdermal Patch Market Size
  - 5.1.4.4 South America Others Market Size
- 5.1.5 South America Opioids Market Size by Drug Class 2019 -2031
  - 5.1.5.1 South America Immediate-Release/Short-Acting Opioids Market Size
  - 5.1.5.2 South America Extended-Release /Long-Acting Opioids Market Size
- 5.1.6 South America Opioids Market Size by End User 2019 -2031
  - 5.1.6.1 South America Hospitals Market Size
  - 5.1.6.2 South America Homecare Market Size
  - 5.1.6.3 South America Speciality Centre Market Size
  - 5.1.6.4 South America Others Market Size
- 5.1.7 South America Opioids Market Size by Distribution Channel 2019 -2031
  - 5.1.7.1 South America Hospital Pharmacy Market Size
  - 5.1.7.2 South America Retail Pharmacy Market Size
  - 5.1.7.3 South America Online Pharmacy Market Size
  - 5.1.7.4 South America Others Market Size
- 5.1.8 South America Opioids Market Size by Conclusion 2019 -2031

This chapter will help you gain Middle East and Africa Market Analysis of Opioids. Further deep in this chapter, you will be able to review Middle East and Africa Opioids Market Split by various segments and Country Split.

Chapter 6 Middle East and Africa Market Analysis

6.1 Middle East and Africa Opioids Market Size 2019 - 2031
- 6.1.1 Middle East and Africa Opioids Market Size By Country 2019 - 2031
- 6.1.2 Middle East and Africa Opioids Market Size by Product 2019 -2031
  - 6.1.2.1 Middle East and Africa Codeine Market Size
  - 6.1.2.2 Middle East and Africa Methadone Market Size
  - 6.1.2.3 Middle East and Africa Morphine Market Size
  - 6.1.2.4 Middle East and Africa Oxycodone Market Size
  - 6.1.2.5 Middle East and Africa Fentanyl Market Size
  - 6.1.2.6 Middle East and Africa Hydrocodone Market Size
  - 6.1.2.7 Middle East and Africa Others Market Size
- 6.1.3 Middle East and Africa Opioids Market Size by Application 2019 -2031
  - 6.1.3.1 Middle East and Africa Pain Management Market Size
  - 6.1.3.2 Middle East and Africa Diarrhea Treatment Market Size
  - 6.1.3.3 Middle East and Africa Cough Treatment Market Size
  - 6.1.3.4 Middle East and Africa Deaddiction Market Size
  - 6.1.3.5 Middle East and Africa Anesthesia Market Size
- 6.1.4 Middle East and Africa Opioids Market Size by Route of Administration 2019 -2031
  - 6.1.4.1 Middle East and Africa Oral Market Size
  - 6.1.4.2 Middle East and Africa Injectable Market Size
  - 6.1.4.3 Middle East and Africa Transdermal Patch Market Size
  - 6.1.4.4 Middle East and Africa Others Market Size
- 6.1.5 Middle East and Africa Opioids Market Size by Drug Class 2019 -2031
  - 6.1.5.1 Middle East and Africa Immediate-Release/Short-Acting Opioids Market Size
  - 6.1.5.2 Middle East and Africa Extended-Release /Long-Acting Opioids Market Size
- 6.1.6 Middle East and Africa Opioids Market Size by End User 2019 -2031
  - 6.1.6.1 Middle East and Africa Hospitals Market Size
  - 6.1.6.2 Middle East and Africa Homecare Market Size
  - 6.1.6.3 Middle East and Africa Speciality Centre Market Size
  - 6.1.6.4 Middle East and Africa Others Market Size
- 6.1.7 Middle East and Africa Opioids Market Size by Distribution Channel 2019 -2031
  - 6.1.7.1 Middle East and Africa Hospital Pharmacy Market Size
  - 6.1.7.2 Middle East and Africa Retail Pharmacy Market Size
  - 6.1.7.3 Middle East and Africa Online Pharmacy Market Size
  - 6.1.7.4 Middle East and Africa Others Market Size
- 6.1.8 Middle East and Africa Opioids Market Size by Conclusion 2019 -2031

Only Available with Corporate User License

Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)

7.1 Country 1 Market Analysis
- 7.1.1 Country 1Opioids Market Size by Product 2019 -2031
- 7.1.2 Country 1Opioids Market Size by Application 2019 -2031
- 7.1.3 Country 1Opioids Market Size by Route of Administration 2019 -2031
- 7.1.4 Country 1Opioids Market Size by Drug Class 2019 -2031
- 7.1.5 Country 1Opioids Market Size by End User 2019 -2031
- 7.1.6 Country 1Opioids Market Size by Distribution Channel 2019 -2031
- 7.1.7 Country 1Opioids Market Size by Conclusion 2019 -2031
7.2 Country 2 Market Analysis
- 7.2.1 Segmentation Analysis will be provided as shown for Country 1
7.3 Country 3 Market Analysis
- 7.3.1 Segmentation Analysis will be provided as shown for Country 1
7.4 Country 4 Market Analysis
- 7.4.1 Segmentation Analysis will be provided as shown for Country 1
7.5 Country 5 Market Analysis
- 7.5.1 Segmentation Analysis will be provided as shown for Country 1
7.6 Country 6 Market Analysis
- 7.6.1 Segmentation Analysis will be provided as shown for Country 1
7.7 Country 7 Market Analysis
- 7.7.1 Segmentation Analysis will be provided as shown for Country 1
7.8 Country 8 Market Analysis
- 7.8.1 Segmentation Analysis will be provided as shown for Country 1
7.9 Country 9 Market Analysis
- 7.9.1 Segmentation Analysis will be provided as shown for Country 1
7.10 Country 10 Market Analysis
- 7.10.1 Segmentation Analysis will be provided as shown for Country 1

This chapter provides an in-depth analysis of the market share among key competitors of Opioids. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.

Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))

8.1 Top Competitors Analysis
- 8.1.1 Top Players Ranking 2022
- (Subject to Data Availability (Private Players))
  
  8.1.2 Global Opioids Market Revenue and Share by Key Players
- 8.1.3 Industry Mergers and Acquisition Analysis
- 8.1.4 New Product Launch Analysis
8.2 Company Profile (Data Subject to Availability)
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.1 Purdue Pharma L.P
  - 8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.1.2 Business Overview
  - 8.2.1.3 Financials (Subject to data availability)
  - 8.2.1.4 Product Types Specification
  - 8.2.1.5 Business Strategy
  - 8.2.1.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.2 Sanofi
  - 8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.2.2 Business Overview
  - 8.2.2.3 Financials (Subject to data availability)
  - 8.2.2.4 Product Types Specification
  - 8.2.2.5 Business Strategy
  - 8.2.2.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.3 Johnson & Johnson Services Inc
  - 8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.3.2 Business Overview
  - 8.2.3.3 Financials (Subject to data availability)
  - 8.2.3.4 Product Types Specification
  - 8.2.3.5 Business Strategy
  - 8.2.3.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.4 AbbVie Inc.
  - 8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.4.2 Business Overview
  - 8.2.4.3 Financials (Subject to data availability)
  - 8.2.4.4 Product Types Specification
  - 8.2.4.5 Business Strategy
  - 8.2.4.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.5 Sun Pharmaceutical Industries Ltd
  - 8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.5.2 Business Overview
  - 8.2.5.3 Financials (Subject to data availability)
  - 8.2.5.4 Product Types Specification
  - 8.2.5.5 Business Strategy
  - 8.2.5.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.6 Pfizer Inc.
  - 8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.6.2 Business Overview
  - 8.2.6.3 Financials (Subject to data availability)
  - 8.2.6.4 Product Types Specification
  - 8.2.6.5 Business Strategy
  - 8.2.6.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.7 Bayer AG
  - 8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.7.2 Business Overview
  - 8.2.7.3 Financials (Subject to data availability)
  - 8.2.7.4 Product Types Specification
  - 8.2.7.5 Business Strategy
  - 8.2.7.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.8 Mallinckrodt Pharmaceuticals
  - 8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.8.2 Business Overview
  - 8.2.8.3 Financials (Subject to data availability)
  - 8.2.8.4 Product Types Specification
  - 8.2.8.5 Business Strategy
  - 8.2.8.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.9 GlaxoSmithKline plc
  - 8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.9.2 Business Overview
  - 8.2.9.3 Financials (Subject to data availability)
  - 8.2.9.4 Product Types Specification
  - 8.2.9.5 Business Strategy
  - 8.2.9.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.10 Aurobindo Pharma
  - 8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.10.2 Business Overview
  - 8.2.10.3 Financials (Subject to data availability)
  - 8.2.10.4 Product Types Specification
  - 8.2.10.5 Business Strategy
  - 8.2.10.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.11 Fresenius Kabi
  - 8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.11.2 Business Overview
  - 8.2.11.3 Financials (Subject to data availability)
  - 8.2.11.4 Product Types Specification
  - 8.2.11.5 Business Strategy
  - 8.2.11.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.12 Amneal Pharmaceuticals
  - 8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.12.2 Business Overview
  - 8.2.12.3 Financials (Subject to data availability)
  - 8.2.12.4 Product Types Specification
  - 8.2.12.5 Business Strategy
  - 8.2.12.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.13 Endo International plc.
  - 8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.13.2 Business Overview
  - 8.2.13.3 Financials (Subject to data availability)
  - 8.2.13.4 Product Types Specification
  - 8.2.13.5 Business Strategy
  - 8.2.13.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.14 Trevena Inc.
  - 8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.14.2 Business Overview
  - 8.2.14.3 Financials (Subject to data availability)
  - 8.2.14.4 Product Types Specification
  - 8.2.14.5 Business Strategy
  - 8.2.14.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.15 Hikma Pharmaceuticals
  - 8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.15.2 Business Overview
  - 8.2.15.3 Financials (Subject to data availability)
  - 8.2.15.4 Product Types Specification
  - 8.2.15.5 Business Strategy
  - 8.2.15.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.16 Rusan Pharma Ltd
  - 8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.16.2 Business Overview
  - 8.2.16.3 Financials (Subject to data availability)
  - 8.2.16.4 Product Types Specification
  - 8.2.16.5 Business Strategy
  - 8.2.16.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.17 Lupin Limited
  - 8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.17.2 Business Overview
  - 8.2.17.3 Financials (Subject to data availability)
  - 8.2.17.4 Product Types Specification
  - 8.2.17.5 Business Strategy
  - 8.2.17.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.18 Abbott Laboratories
  - 8.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.18.2 Business Overview
  - 8.2.18.3 Financials (Subject to data availability)
  - 8.2.18.4 Product Types Specification
  - 8.2.18.5 Business Strategy
  - 8.2.18.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.19 Novartis AG
  - 8.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.19.2 Business Overview
  - 8.2.19.3 Financials (Subject to data availability)
  - 8.2.19.4 Product Types Specification
  - 8.2.19.5 Business Strategy
  - 8.2.19.6 S.W.O.TAnalysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  8.2.20 Assertio Therapeutics Inc.+
  - 8.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 8.2.20.2 Business Overview
  - 8.2.20.3 Financials (Subject to data availability)
  - 8.2.20.4 Product Types Specification
  - 8.2.20.5 Business Strategy
  - 8.2.20.6 S.W.O.TAnalysis

This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.

Chapter 9 Qualitative Analysis (Subject to Data Availability)

9.1 Market Drivers
9.2 Market Restraints
9.3 Market Trends
9.4 Market Opportunity
9.5 Technological Road Map (Subject to Data Availability)
9.6 Product Life Cycle (Subject to Data Availability)
9.7 Consumer Preference Analysis
9.8 Market Attractiveness Analysis
9.9 PESTEL Analysis
- 9.9.1 Political Factors
- 9.9.2 Economic Factors
- 9.9.3 Social Factors
- 9.9.4 Technological Factors
- 9.9.5 Legal Factors
- 9.9.6 Environmental Factors
9.10 Industrial Chain Analysis (Subject to Data Availability)
- 9.10.1 Industry Chain Analysis
- 9.10.2 Manufacturing Cost Analysis
- 9.10.3 Supply Side Analysis
  - 9.10.3.1 Raw Material Analysis
  - 9.10.3.2 Raw Material Procurement Analysis
  - 9.10.3.3 Raw Material Price Trend Analysis
9.11 Porter’s Five Forces Analysis
- 9.11.1 Bargaining Power of Suppliers
- 9.11.2 Bargaining Power of Buyers
- 9.11.3 Threat of New Entrants
- 9.11.4 Threat of Substitutes
- 9.11.5 Degree of Competition
9.12 Patent Analysis (Subject to Data Availability)
9.13 ESG Analysis

Segmentation Product Analysis 2019 -2031, will provide market size split by Product. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.

Chapter 10 Market Split by Product Analysis 2019 -2031

10.1 Codeine
- 10.1.1 Global Opioids Revenue Market Size and Share by Codeine 2019 -2031
10.2 Methadone
- 10.2.1 Global Opioids Revenue Market Size and Share by Methadone 2019 -2031
10.3 Morphine
- 10.3.1 Global Opioids Revenue Market Size and Share by Morphine 2019 -2031
10.4 Oxycodone
- 10.4.1 Global Opioids Revenue Market Size and Share by Oxycodone 2019 -2031
10.5 Fentanyl
- 10.5.1 Global Opioids Revenue Market Size and Share by Fentanyl 2019 -2031
10.6 Hydrocodone
- 10.6.1 Global Opioids Revenue Market Size and Share by Hydrocodone 2019 -2031
10.7 Others
- 10.7.1 Global Opioids Revenue Market Size and Share by Others 2019 -2031

The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.

Chapter 11 Market Split by Application Analysis 2019 -2031

11.1 Pain Management
- 11.1.1 Global Opioids Revenue Market Size and Share by Pain Management 2019 - 2031
11.2 Diarrhea Treatment
- 11.2.1 Global Opioids Revenue Market Size and Share by Diarrhea Treatment 2019 - 2031
11.3 Cough Treatment
- 11.3.1 Global Opioids Revenue Market Size and Share by Cough Treatment 2019 - 2031
11.4 Deaddiction
- 11.4.1 Global Opioids Revenue Market Size and Share by Deaddiction 2019 - 2031
11.5 Anesthesia
- 11.5.1 Global Opioids Revenue Market Size and Share by Anesthesia 2019 - 2031

Chapter 12 Market Split by Route of Administration Analysis 2019 -2031

12.1 Oral
- 12.1.1 Global Opioids Revenue Market Size and Share by Oral 2019 -2031
12.2 Injectable
- 12.2.1 Global Opioids Revenue Market Size and Share by Injectable 2019 -2031
12.3 Transdermal Patch
- 12.3.1 Global Opioids Revenue Market Size and Share by Transdermal Patch 2019 -2031
12.4 Others
- 12.4.1 Global Opioids Revenue Market Size and Share by Others 2019 -2031

Chapter 13 Market Split by Drug Class Analysis 2019 -2031

13.1 Immediate-Release/Short-Acting Opioids
- 13.1.1 Global Opioids Revenue Market Size and Share by Immediate-Release/Short-Acting Opioids 2019 -2031
13.2 Extended-Release /Long-Acting Opioids
- 13.2.1 Global Opioids Revenue Market Size and Share by Extended-Release /Long-Acting Opioids 2019 -2031

Chapter 14 Market Split by End User Analysis 2019 -2031

14.1 Hospitals
- 14.1.1 Global Opioids Revenue Market Size and Share by Hospitals 2019 -2031
14.2 Homecare
- 14.2.1 Global Opioids Revenue Market Size and Share by Homecare 2019 -2031
14.3 Speciality Centre
- 14.3.1 Global Opioids Revenue Market Size and Share by Speciality Centre 2019 -2031
14.4 Others
- 14.4.1 Global Opioids Revenue Market Size and Share by Others 2019 -2031

Chapter 15 Market Split by Distribution Channel Analysis 2019 -2031

15.1 Hospital Pharmacy
- 15.1.1 Global Opioids Revenue Market Size and Share by Hospital Pharmacy 2019 -2031
15.2 Retail Pharmacy
- 15.2.1 Global Opioids Revenue Market Size and Share by Retail Pharmacy 2019 -2031
15.3 Online Pharmacy
- 15.3.1 Global Opioids Revenue Market Size and Share by Online Pharmacy 2019 -2031
15.4 Others
- 15.4.1 Global Opioids Revenue Market Size and Share by Others 2019 -2031

Chapter 16 Market Split by Conclusion Analysis 2019 -2031

This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Opioids market

Chapter 17 Research Findings

17.1 Key Takeaways
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

17.2 Analyst Point of View
17.3 Assumptions and Acronyms